NO20083549L - Peptiddomene nodvendig for interaksjon mellom kappen av et virus, HERV-W interferensgruppen, og en HASCT-reseptor - Google Patents

Peptiddomene nodvendig for interaksjon mellom kappen av et virus, HERV-W interferensgruppen, og en HASCT-reseptor

Info

Publication number
NO20083549L
NO20083549L NO20083549A NO20083549A NO20083549L NO 20083549 L NO20083549 L NO 20083549L NO 20083549 A NO20083549 A NO 20083549A NO 20083549 A NO20083549 A NO 20083549A NO 20083549 L NO20083549 L NO 20083549L
Authority
NO
Norway
Prior art keywords
amino acids
cysteine
endpoint
herv
envelope
Prior art date
Application number
NO20083549A
Other languages
English (en)
Inventor
Francois Mallet
Guy Oriol
Valerie Cheynet
Original Assignee
Biomerieux Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux Sa filed Critical Biomerieux Sa
Publication of NO20083549L publication Critical patent/NO20083549L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10061—Methods of inactivation or attenuation
    • C12N2740/10063—Methods of inactivation or attenuation by chemical treatment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Den foreliggende oppfinnelsen er relatert til et peptiddomene nødvendig for interaksjon mellom hylsteret av et virus tilhørende HERV-W interferensgruppen og en hASCT reseptor, omfattende et N-endepunkt og et C-endepunkt. Nevnte peptiddomene er definert, ved N-endepunktet derav, ved et mønster dannet ved aminosyrene L (Z)a-prolin-cystein-X-cystein, hvor Z er enhver aminosyre, a er et heltall mellom 2 og 30 og X er enhver aminosyre, og ved C-endepunktet derav, ved et mønster dannet ved aminosyrene serin-asparginsyre-Xa-Xb-Xc-Xd-Xe,-asparginsyre-Xf-Xg-(Z)ß, hvor Xa, Xb, Xc, Xd, Xe, Xf, Xg er hvilke som helst aminosyrer, Z er enhver aminosyre, ß er et heltall mellom 15 og 25, fortrinnsvis 20. Peptiddomenet omfatter, mellom N-endepunktet og C-endepunktet, minst ett mønster valgt fra de følgende mønstere: Et mønster dannet ved aminosyrene cystein-tyrosin-X2-X3-X4-X5-X6-cystein, hvor X2, X3, X4, X5, X6 er hvilke som helst aminosyrer, og et mønster dannet ved aminosyrene cystein-X7-X8-X9-X10-X11-X12-X13-X14-X15-cystein-tryptofan hvor X7, X8, X9, X10, X11, X12, X13, X14, X15 er hvilke som helst aminosyrer.
NO20083549A 2006-02-09 2008-08-14 Peptiddomene nodvendig for interaksjon mellom kappen av et virus, HERV-W interferensgruppen, og en HASCT-reseptor NO20083549L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0650468A FR2897062B1 (fr) 2006-02-09 2006-02-09 Domaine peptidique necessaire a l'interaction entre l'enveloppe d'un virus appartenant au groupe d'interference de herv-w et un recepteur asct
PCT/FR2007/000236 WO2007090967A2 (fr) 2006-02-09 2007-02-09 Domaine peptidique necessaire a l'interaction entre l'enveloppe d'un virus appartenant au groupe d'interference de herv-w et un recepteur hasct

Publications (1)

Publication Number Publication Date
NO20083549L true NO20083549L (no) 2008-11-07

Family

ID=37037521

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083549A NO20083549L (no) 2006-02-09 2008-08-14 Peptiddomene nodvendig for interaksjon mellom kappen av et virus, HERV-W interferensgruppen, og en HASCT-reseptor

Country Status (15)

Country Link
US (2) US20090148454A1 (no)
EP (1) EP1981904B9 (no)
JP (2) JP2009525741A (no)
CN (1) CN101379079B (no)
AU (1) AU2007213591B2 (no)
CA (1) CA2640793C (no)
DK (1) DK1981904T3 (no)
ES (1) ES2637961T3 (no)
FR (1) FR2897062B1 (no)
HU (1) HUE034297T2 (no)
IL (1) IL193353A (no)
NO (1) NO20083549L (no)
PL (1) PL1981904T3 (no)
PT (1) PT1981904T (no)
WO (1) WO2007090967A2 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1007376B1 (pt) * 2009-01-09 2022-03-22 Centre National De La Recherche Scientifique Novos ligantes de ligação a receptores e seu uso na detecção de células de interesse biológico
CN102281892A (zh) 2009-01-13 2011-12-14 特朗斯吉有限公司 酿酒酵母线粒体核酸级分用于免疫刺激的用途
JP2018531599A (ja) * 2015-10-05 2018-11-01 メタフォラ，バイオシステムズ 膵臓癌の検出、診断および処置のための受容体結合ドメインリガンド
WO2024121254A1 (en) * 2022-12-06 2024-06-13 Metafora Biosystems Ligands specific for asct1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2710075B1 (fr) 1993-09-15 1995-10-27 Bio Merieux Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal.
FR2781802B1 (fr) * 1998-07-31 2001-05-11 Bio Merieux Derives satures ou insatures de l'abietane, conjugues derives et utilisations dans une composition diagnostique, un reactif et un dispositif
FR2865403B1 (fr) * 2004-01-23 2009-06-12 Biomerieux Sa Composition pour le traitement d'une pathologie associee a la msrv/herv-w

Also Published As

Publication number Publication date
JP2009525741A (ja) 2009-07-16
CN101379079A (zh) 2009-03-04
WO2007090967A2 (fr) 2007-08-16
JP2016040295A (ja) 2016-03-24
EP1981904B1 (fr) 2017-04-05
JP6494487B2 (ja) 2019-04-03
US20090148454A1 (en) 2009-06-11
US10040829B2 (en) 2018-08-07
WO2007090967A3 (fr) 2007-12-21
ES2637961T3 (es) 2017-10-18
FR2897062A1 (fr) 2007-08-10
EP1981904B9 (fr) 2017-09-13
US20160090402A1 (en) 2016-03-31
EP1981904A2 (fr) 2008-10-22
IL193353A (en) 2016-06-30
FR2897062B1 (fr) 2011-11-04
DK1981904T3 (en) 2017-07-10
AU2007213591B2 (en) 2011-10-06
IL193353A0 (en) 2011-08-01
HUE034297T2 (en) 2018-02-28
AU2007213591A1 (en) 2007-08-16
CA2640793A1 (fr) 2007-08-16
CN101379079B (zh) 2012-11-14
CA2640793C (fr) 2015-11-24
PL1981904T3 (pl) 2017-09-29
PT1981904T (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
V’kovski et al. Coronavirus biology and replication: implications for SARS-CoV-2
NO20083549L (no) Peptiddomene nodvendig for interaksjon mellom kappen av et virus, HERV-W interferensgruppen, og en HASCT-reseptor
MX2009009174A (es) Inhibidores de serina-proteasas para el tratamiento de infecciones por el virus de hepatitis c.
TW200802083A (en) Technique for setting a vector mask
NO20025318D0 (no) FremgangsmÕte for rensing av syntesegass
Ionescu An overview of the crystallized structures of the SARS-CoV-2
DK1987052T3 (da) Syntese af glucagonlignende peptider
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
MY139896A (en) Improved prrs vaccines
DK1383795T3 (da) Rekombinant nucleoproteinmutant fra Newcastle disease-virus som markörvaccine
ATE297910T1 (de) Retinoid x rezeptormodulatoren
NO20033272D0 (no) En sykdom i luftveiene hos mottakelige pattedyr forårsaket av et virus
WO2004041201A3 (en) Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
JO2593B1 (en) Protease inhibitors NS3 hepatitis C HCV virus
CL2011002426A1 (es) Compuestos derivados de benzo-diazol pirrolidina sustituidos, inhibidores de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica; y su uso para el tratamiento de una infeccion por vhc.
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20054669L (no) Substituerte kinobenzoxazinanaloger
TR201907381T4 (tr) Beta-laktamil fenilalanin, sistein ve serin vazopressin antagonisti.
EA200870491A1 (ru) Новое применение эсциталопрама
NO20082904L (no) Feksofenadinsupensjonsformulering
CY1110098T1 (el) Βιομηχανικη μεθοδος για τη παρασκευη της γαμμα-λακτονης του 17-υδροξυ-6-βητα,7-βητα, 15-βητα,16-βητα-δις-μεθυλενο-3-οξο-17-αλφα πρεγκν-4-ενο-21-καρβοξυλικου οξεος και ενδιαμεσα κλειδια για την μεθοδο αυτη
HK1111168A1 (en) A PROCESS FOR THE PREPARATION OF 17-HYDROXY-6 ß,7ß,15 ß,16 ß - BISMETHYLENE-17a-PREGN-4-ENE-3-ONE-21-CARBOXYLIC ACID Y-LACTONE AND KEY-INTERMEDIATES FOR THIS PROCESS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application